Study presents rare cases of COVID-19-associated pulmonary aspergillosis

By Neha MathurReviewed by Aimee MolineuxOct 14 2022

A recent study published in the Indian Journal of Critical Care Medicine presented a case series of patients with coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA). The goal of the study was to inform clinicians and healthcare workers of this serious COVID-19-related complication.

Background

Many atypical radiological signs of COVID-19 and invasive pulmonary aspergillosis (IPA) mimic each other. Although IPA is most common in immunocompromised patients, influenza infection also increases its risk in non-neutropenic patients. Respiratory viruses damage the respiratory epithelium and paralyze the local immune system. This damage leads to secondary and opportunistic infections, including invasive fungal infections.

Thus, critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS) admitted to intensive care units (ICUs) are prone to developing CAPA. Keeping this in mind and the occurrence of influenza-associated aspergillosis (IAA), IPA diagnosis is a must for COVID-19 patients as well. However, it is worth noting that radiology alone cannot always accurately diagnose CAPA in COVID-19 patients.

About the study

In the present study, researchers retrospectively reviewed the medical charts of all the COVID-19 patients who visited the Orchid Medical Centre in Ranchi, India. These patients had reverse transcription-polymerase chain reaction (RT-PCR)-confirmed COVID-19. First, the doctors prescribed supportive home treatment. However, when the patient's symptoms worsened, they advised hospital admission for further diagnosis and treatment.

Study findings

High-resolution computed tomography (HRCT) showed cavitary lesions in the lungs of these patients. Although HRCT findings pointed to the possibility of CAPA, they also performed a serum galactomannan test to enhance the diagnosis. Serum galactomannan assay was positive for all the patients. Due to the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and aerosolization, doctors avoided bronchoscopy. Instead, they prescribed an antifungal drug, voriconazole, at a dosage of 6 mg/kg every 12 hours intravenously for the first two days, followed by 4 mg/kg every 12 hours (maintenance dose).

Other ICU patients did not develop IPA, and even these patients were not immunocompromised. In the absence of any other factor that made these patients prone to this infection, severe COVID-19 emerged as the sole reason for developing IPA.

Conclusions

To summarize,  it is difficult to differentiate between fungal colonization and invasive disease without bronchoscopic sampling and microscopic evaluation of fungal cultures. Antigen-based laboratory test galactomannan assay supports IPA diagnosis, but a more thorough approach is needed to define and diagnose IPA in COVID-19 patients. For instance, tissue culture and tissue microscopy of primarily sterile specimens showing invasive growth of septate fungal hyphae could confirm IPA diagnosis. Further, despite the risk posed by biopsies in COVID-19 patients, bronchoalveolar lavage fluid and lung biopsy are the best sample types to confirm IPA diagnosis in COVID-19 patients.

The present case series indicated an increased risk of developing IPA in critically ill COVID-19 patients, delayed diagnosis of which could translate into increased mortality and unnecessary burden on healthcare systems. Thus, clinicians should always look for CAPA in critically ill COVID-19 patients who are unresponsive to the treatment.